Proteomic identification of a marker signature for MAPKi resistance in melanoma.
Paulitschke V, Eichhoff O, Gerner C, Paulitschke P, Bileck A, Mohr T, Cheng PF, Leitner A, Guenova E, Saulite I, Freiberger SN, Irmisch A, Knapp B, Zila N, Chatziisaak TP, Stephan J, Mangana J, Kunstfeld R, Pehamberger H, Aebersold R, Dummer R, Levesque MP.
EMBO J. 2019 Aug 1;38(15):e95874. doi: 10.15252/embj.201695874. Epub 2019 Jun 26. PMID: 31267558

Proteomics-based insights into mitogen-activated protein kinase inhibitor resistance of cerebral melanoma metastases.
Zila N, Bileck A, Muqaku B, Janker L, Eichhoff OM, Cheng PF, Dummer R, Levesque MP, Gerner C, Paulitschke V.
Clin Proteomics. 2018 Mar 9;15:13. doi: 10.1186/s12014-018-9189-x. eCollection 2018. PMID: 29541007

Proteome analysis identifies L1CAM/CD171 and DPP4/CD26 as novel markers of human skin mast cells.
Gschwandtner M, Paulitschke V, Mildner M, Brunner PM, Hacker S, Eisenwort G, Sperr WR, Valent P, Gerner C, Tschachler E.
Allergy. 2017 Jan;72(1):85-97. doi: 10.1111/all.12919. Epub 2016 May 25. PMID: 27091730

Proteomics approaches to understanding mitogen-activated protein kinase inhibitor resistance in melanoma.
Paulitschke V, Eichhoff O, Cheng PF, Levesque MP, Höller C.
Curr Opin Oncol. 2016 Mar;28(2):172-9. doi: 10.1097/CCO.0000000000000261. Review. PMID: 26742019

Vemurafenib resistance signature by proteome analysis offers new strategies and rational therapeutic concepts.
Paulitschke V, Berger W, Paulitschke P, Hofstätter E, Knapp B, Dingelmaier-Hovorka R, Födinger D, Jäger W, Szekeres T, Meshcheryakova A, Bileck A, Pirker C, Pehamberger H, Gerner C, Kunstfeld R.
Mol Cancer Ther. 2015 Mar;14(3):757-68. doi: 10.1158/1535-7163.MCT-14-0701. Epub 2015 Jan 22. PMID: 25612618

Proteome profiling of keratinocytes transforming to malignancy.
Paulitschke V, Gerner C, Hofstätter E, Mohr T, Mayer RL, Pehamberger H, Kunstfeld R.
Electrophoresis. 2015 Feb;36(4):564-76. doi: 10.1002/elps.201400309. Epub 2015 Jan 28. PMID: 25395074

Functional classification of cellular proteome profiles support the identification of drug resistance signatures in melanoma cells.
Paulitschke V, Haudek-Prinz V, Griss J, Berger W, Mohr T, Pehamberger H, Kunstfeld R, Gerner C.
J Proteome Res. 2013 Jul 5;12(7):3264-76. doi: 10.1021/pr400124w. Epub 2013 Jun 19. PMID: 23713901

Proteome analysis identified the PPARγ ligand 15d-PGJ2 as a novel drug inhibiting melanoma progression and interfering with tumor-stroma interaction.
Paulitschke V, Gruber S, Hofstätter E, Haudek-Prinz V, Klepeisz P, Schicher N, Jonak C, Petzelbauer P, Pehamberger H, Gerner C, Kunstfeld R.
PLoS One. 2012;7(9):e46103. doi: 10.1371/journal.pone.0046103. Epub 2012 Sep 25. PMID: 23049949

3,3',4,4',5,5'-hexahydroxystilbene impairs melanoma progression in a metastatic mouse model.
Paulitschke V, Schicher N, Szekeres T, Jäger W, Elbling L, Riemer AB, Scheiner O, Trimurtulu G, Venkateswarlu S, Mikula M, Swoboda A, Fiebiger E, Gerner C, Pehamberger H, Kunstfeld R.
J Invest Dermatol. 2010 Jun;130(6):1668-79. doi: 10.1038/jid.2009.376. Epub 2009 Dec 3. PMID: 19956188

Entering a new era of rational biomarker discovery for early detection of melanoma metastases: secretome analysis of associated stroma cells.
Paulitschke V, Kunstfeld R, Mohr T, Slany A, Micksche M, Drach J, Zielinski C, Pehamberger H, Gerner C.
J Proteome Res. 2009 May;8(5):2501-10. doi: 10.1021/pr8010827. PMID: 19222175